α₁ -antitrypsin Pittsburgh and plasmin-mediated proteolysis.

Area of Science:

• Biochemistry
• Hematology
• Genetics

Background:

• Alpha-1-antitrypsin (α1-AT) Pittsburgh is a rare genetic variant of α1-antitrypsin.
• Patients with α1-AT Pittsburgh typically present with a mild bleeding tendency.
• This variant has a specific mutation (Met358 to Arg) at the reactive site, conferring potent thrombin inhibitory activity.

Purpose of the Study:

• To investigate the antifibrinolytic potential of α1-AT Pittsburgh.
• To determine if the antifibrinolytic properties contribute to the observed mild bleeding phenotype in patients.
• To further characterize the hemostatic balance in individuals with α1-AT Pittsburgh.

Main Methods:

• Assessed fibrinolysis inhibition using patient plasma and purified wild-type and Pittsburgh α1-AT.
• Employed electrophoretic zymography, western blotting, and clot fibrinolysis assays.
• Evaluated the inhibitory potential against tissue plasminogen activator and plasmin.

Main Results:

• α1-AT Pittsburgh demonstrated significant inhibition of tissue plasminogen activator (t-PA).
• The variant protein also potently inhibited plasmin, a key enzyme in clot degradation.
• Patient plasma containing α1-AT Pittsburgh exhibited strong antifibrinolytic activity.

Conclusions:

• The antifibrinolytic activity of α1-AT Pittsburgh is a significant finding.
• This dual inhibition (thrombin and fibrinolysis) likely explains the mild bleeding phenotype.
• The study highlights the complex role of α1-AT variants in hemostasis.